Vesely D L
Diabetologia. 1982 Apr;22(4):269-72. doi: 10.1007/BF00281304.
Glibenclamide enhanced the activity in the rat of guanylate cyclase in a number of extra-pancreatic tissues. Thus, glibenclamide enhanced guanylate cyclase activity in vitro two- to threefold in liver, kidney, heart, spleen and colon at a concentration of 1 mumol/l. Dose-response curves of glibenclamide on hepatic guanylate cyclase revealed that more than half-maximal stimulation was observed at a concentration as low as 10 nmol/l (p less than 0.001) and no stimulation of guanylate cyclase was seen when the concentration was decreased to 1 nmol/l. Maximal enhancement was seen at 100 nmol/l of glibenclamide. Varying the concentration of the guanylate cyclase co-factor manganese had no effect on the glibenclamide enhancement of guanylate cyclase. In addition to the increased insulin receptors found recently in monocytes and fibroblasts, the present findings may help explain the extra-pancreatic effects of glibenclamide and possibly of other sulphonylurea drugs.
格列本脲增强了大鼠多种胰腺外组织中鸟苷酸环化酶的活性。因此,在体外,格列本脲在浓度为1微摩尔/升时可使肝脏、肾脏、心脏、脾脏和结肠中的鸟苷酸环化酶活性提高两到三倍。格列本脲对肝脏鸟苷酸环化酶的剂量反应曲线显示,在低至10纳摩尔/升的浓度下即可观察到超过半数最大刺激作用(p小于0.001),而当浓度降至1纳摩尔/升时则未观察到对鸟苷酸环化酶的刺激作用。格列本脲浓度为100纳摩尔/升时可出现最大增强作用。改变鸟苷酸环化酶辅因子锰的浓度对格列本脲增强鸟苷酸环化酶的作用没有影响。除了最近在单核细胞和成纤维细胞中发现的胰岛素受体增加外,目前的研究结果可能有助于解释格列本脲以及其他磺酰脲类药物的胰腺外作用。